Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Second HER-2 breast cancer test gets US approval

This article was originally published in Clinica

Executive Summary

The US FDA last week approved Ventana Medical Systems' Pathway test as an aid in identifying which breast cancer patients would benefit from treatment with Genentech's Herceptin (trastuzumab) therapy. The test has been a long time coming, but its arrival means that US oncologists will now have double the gene test armoury with which to assess the likely response to Herceptin therapy in patients with breast cancer, a condition that strikes over 180,000 women in the US every year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT075368

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel